No matter how many times generic manufacturers kick the door blocking entry of Copaxone lookalikes, Teva (NYSE:TEVA) has been able to keep it closed. Yesterday’s US patent decision shows just how big the cracks are getting, but until challengers have knocked away every last scrap of intellectual property the Israel-based group will still have a big seller.
Exclusivity of the original daily 20mg dose of the multiple sclerosis (MS) treatment evaporated in 2015, of course, but Teva has been masterful at persuading patients to switch to a 40mg formulation used three times a week. Special US patent judges ruled yesterday that a bigger dose was not enough of a change to warrant additional protection, but it could take many months more to firm up generic competitors’ legal standing.

